Background: Subjects with depression are more prone to develop cardiovascular complications. Severity of depression is associated with higher rates of cardiovascular mortality and morbidity. Several mechanisms were suggested including accelerated atherosclerosis, alteration of the cardiac autonomic response with a decrease in heart rate variability. There is evidence that circulating endothelial progenitor cells (EPCs) are decreased in patients with major depression. Our hypothesis was that patients with depression would have an impaired ability to build colonies of EPCs. Methods: A prospective study enrolled twenty women with a diagnosis of major. All were not treated before for depression. Thirteen healthy age-matched women served as controls. All signed a consent form before recruitment to the study. Peripheral blood was drawn to build colonies of EPCs within 5 days. ELISA methods were used to measure levels of vascular cell adhesion molecule-1 (VCAM-1) and vascular endothelial growth factor (VEGF). Results: Twenty female patients with depression were recruited. The mean age was 43 6 14 years (vs. controls 41 6 11 years, P ¼ 0.682), patients' average CFU-EPCs was 7 6 8 colonies per well (controls 31 6 11, P ¼ 0.0001), VCAM-1 level was 121.7 6 3.0 ng/ml (controls 119.3 6 3.1 pg/ml, P ¼ 0.037), VEGF level was 6.4 6 0.2 pg/ml (controls 5.2 6 0.5 pg/ml, P ¼ 0.0001). An inverse correlation was found between VEGF level and EPCs' colonies (r ¼ À0.547, P < 0.001) and between age and CFU-EPCs (r ¼ À0.576, P ¼ 0.008). Conclusions: We found that patients with major depression had high levels of VCAM-1 and VEGF. They also had a significant inhibition of EPCs' colonies. An inverse correlation was found between levels of VEGF and the ability to grow colonies of EPCs in culture.
Background
Subjects with depression are more prone to develop cardiovascular complications. Severity of depression is associated with higher rates of cardiovascular mortality and morbidity. Depression is a powerful predictor of survival after acute myocardial infarction and also in patients with heart failure. 1 The association between depression and coronary heart disease related death may reflect the association of depression with sudden death, and indeed, a prospective study found that the risk of cardiac arrest was higher in less depressed patients compared with non-depressed subjects, and it was further increased in severely depressed subjects. 2 Several mechanisms were suggested including accelerated atherosclerosis, alteration of the cardiac autonomic response with a decrease in heart rate variability. 3, 4 Low level of three polyunsaturated fatty acids in red blood cell membranes is associated with sudden cardiac death and has been reported in patients with major depression. 5, 6 Besides, patients with depression keep poor adherence to treatment and have an unhealthy life style habits. 7 In the Maastricht study (a population-based cohort study with 852 patients with depression) high levels of biomarkers of inflammation (hs-CRP, TNF-a, serum amyloid type A (SAA), soluble inter cellular adhesion molecule 1 (sICAM-1)) and biomarkers of endothelial function (sICAM-1 and sE-Selectin) were associated with depression. 8 Inflammation and endothelial dysfunction are both associated with depression, and may be the mechanism that causes cardiovascular events. Another possible mechanism could be through a nitric oxide (NO) pathway. Asymmetric di methyl arginine (ADMA) concentration were significantly elevated in patients with depression, and decreased when a clinical improvement in depression was achieved (with a concomitant decrease in arginase activity, an increased L-arginine/ADMA ratio and a trend to increase global arginine bioavailability). 9 There is evidence that circulating endothelial progenitor cells (EPCs) are decreased in patients with major depression. 10 Our hypothesis was that patients with depression would have an impaired ability to build colonies of EPCs; not just a decrease in the number of circulating EPCs (diagnosed by flow cytometry as CD133 þ CD34 þ KDRþ), but a functional impairment in the ability to regenerate damaged blood vessels or create new blood vessels-by an impaired ability to build colony forming units of endothelial progenitor cells (CFU-EPCs). In order to better understand the mechanism and the association between stem cells and depression we also measured level of markers of endothelial activation and vascular growth factors.
Methods
A prospective study that enrolled 20 women with a recently diagnosed major depression (based on DSW 5) admitted to the Psychiatric Department for the first time. All were not treated before for depression. All had no known cardiac disease nor any chronic disease like type 2 diabetes mellitus, hypertension, renal failure, an autoimmune/inflammatory disease, hypercholesterolemia nor hypertriglyceridemia. Thirteen healthy age matched women were recruited as the control group.
All signed a consent form before recruitment to the study. Peripheral blood was drawn early in the morning (fasting) and was processed within 1 h for the ability to build CFU-EPCs (the Hill protocol-A).
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Growth of CFU-EPCs
The investigator who performed the laboratory experiments was blinded to the patients' clinical data. Venous blood samples were drawn from an antecubital vein into ethylene diamine tetra acetic acid-containing tubes. Forty milliliters of blood were processed; peripheral blood mononuclear cells were isolated by Ficoll density-gradient centrifugation, washed twice in phosphate-buffered saline with 5% fetal bovine serum, and resuspended in media (EndoCult basal media with supplements; StemCell Technologies, Vancouver BC Canada, for EPC colonyforming assay). Cells were plated on human fibronectin-coated plates (BIOCOAT; Becton Dickinson Labware Bedford Mass) at a density of 5 A central cluster alone without associated emerging cells, the 'sunflower' image, was not counted as a colony. Colonies were counted manually in a minimum of eight wells by observers who were unaware of the subjects' clinical profiles.
Markers of endothelial activation/function and vascular growth factors were measured using ELISA methods. Blood samples for laboratory assays were obtained between 8 and 10 am, patients were fasting and the samples were immediately coded so that investigators performing laboratory assays would be blinded to subject identity or study sequence. Plasma and serum were separated by centrifugation and stored at À80 C until analysis. Vascular cell adhesion molecule 1 (VCAM-1) represents activation of blood vessels during vascular inflammation (the rolling of WBCs turns into firm adhesion), and vascular endothelial growth factor (VEGF) is a known growth factor of blood vessels at different stages of de novo generation or regeneration of damaged blood vessels and accompanies vasculogenesis and angiogenesis. All will be measured by enzyme-linked immune-sorbent assays (R&D Systems, Minneapolis, MN USA).
Statistical analysis
Data are expressed as means 6 SD. A non-parametric t-test was utilized to compare the number of CFU-EPCs, E selectin, VCAM-1, and VEGF level between patients and healthy controls. We also performed a Pearson correlation between all variables among patients with depression in order to find association between the different markers of vascular activation and CFUEPCs.
Results
Patients' age was 43-6 14-years old (healthy controls 41-6 11-years old, P ¼ 0.682), patients' average 'CFU-EPCs' was 7 6 8 colonies per well (after counting 8 wells) (controls 31 6 11 CFUEPCs, P ¼ 0.0001), soluble 'VCAM-1' level was 121.7 6 3.0 ng/ml (controls 119.3 6 3.1 pg/ml, P ¼ 0.037), and 'VEGF' level was 6.4 6 0.2 pg/ml (controls 5.2 6 0.5 pg/ml, P ¼ 0.0001) ( Table 1) . Depressed patients (all women) had higher levels of markers of inflammation and vascular reactivity, and a significantly lower count of colonies of endothelial stem cells.
Using Pearson correlation we found among the depressed patients an inverse correlation between VEGF levels and the ability to grow colonies of endothelial stem cells (r ¼ À0.547, P < 0.001), and an inverse correlation between age and CFU-EPCs (r ¼ À0.576, P ¼ 0.008), which means that older depressed patients had less colonies than the younger ones ( Table  2 ).
Discussion
We found that our patients, all women with major depression who did not receive any anti-depressive therapy, had an impaired ability to grow CFU-EPCs in culture with low counts of EPCs compared with healthy controls, and had high levels of VCAMs and VEGF factor. An inverse correlation was found between levels of VEGF and the CFU-EPCs, which means that the higher VEGF level the more severe the impairment was. We also found that older patients had a greater disability to grow colonies; thus, higher levels of VEGF and old age impair the ability for blood vessels' regeneration in patients with major depression.
Depression has been associated with cardiovascular death for years. 12 Depression has been associated with cardiovascular morbidity and mortality. [13] [14] [15] [16] [17] Depression doubles the risk of development of new cardiovascular disease. 18 A longitudinal study of Danes demonstrated that depression predicted a 70% increase in myocardial infarction and a 60% increase in allcause mortality. 19 A case-control study, the INTERHEART study found that the four most important risk factors to develop cardiac disease are a comprehensive lipid profile, psychological factors (depression), smoking and diabetes mellitus. 20 Depression is a powerful predictor of survival after myocardial infarction, 18, 21, 22 and in patients with heart failure. [23] [24] [25] Depressed patients post myocardial infarction had a 3-fold increase in mortality in 5 years, with a gradient relationship with the degree of depression. 25 Clinically depressed patients had higher odds ratio of cardiac arrest in both sexes, in different age groups, with and without known heart disease. The risk of cardiac arrest was increased in patients with moderate depression (odds ratio of 1.3) and further increased in severely depressed subjects (odds ratio of 1.77). 2 Among cardiac patients, compared with non-depressed cardiac patients, the risk of future cardiac death was 1.6 for those who suffered minor depression and 3 for patients with major depression. 26 There are several putative mechanisms that are trying to explain this phenomenon, including alterations in the autonomic nervous system, 27 We investigated the possible mechanism of inflammation and endothelial dysfunction as possible mechanisms. The Maastricht study has demonstrated that depression is associated with elevated levels of inflammatory (hs-CRP, SAA, sICAM-1, IL-6, IL-8, TNF-a) and endothelial markers (sICAM-1, sE-selectin). 8 Previous studies have shown that pro-inflammatory cytokines may cause depressive disorder, via immune to brain communication where pro-inflammatory cytokines caused feeling of depression through different pathways. The first suggested pathway is the neural, locally produced cytokines activate primary afferent nerves in the brain during an infection. 32 The second pathway is the humoral, Toll-like receptors outside the blood-brain barrier (BBB) produce pro-inflammatory cytokines that enter the BBB through diffusion. 33 The third hypothesis suggests cytokine transport through the BBB, an overflow of pro inflammatory cytokines that overflow from the systemic circulation and enter through cytokine transporters through the BBB. 34 A fourth possible mechanism involves IL-1 receptors located on endothelial cells of the blood vessels of the brain. Activation of these receptors by systemic circulating cytokines produces prostaglandins that act within the brain and lead to the production of pro inflammatory cytokine within the brain, which induce symptoms of depression. 35, 36 Another hypothesis postulates that vascular damage in the brain predisposes to depressive symptoms through damage caused to deep and frontal brain structures involved in mood regulation. 37 In our study levels of VCAM-1 were significantly increased in depressed patients and it strengthen the inflammatory theory of depression. In order to understand the effect of inflammation (related with depression) on blood vessels' reactivity we had to explore markers of vascular function, like VEGF and endothelial function.
Vascular endothelial dysfunction is another pathway that could link depression to cardiovascular events. Flow mediated dilatation (FMD) of the brachial artery is a non-invasive approach to measure endothelial function (clinically) and is related with coronary artery dysfunction and cardiovascular risk factors. [38] [39] [40] [41] It has been demonstrated that depression may have an increased risk of cardiovascular events because of the association with endothelial dysfunction-the leading pathway to atherosclerosis. 42 Patients with depression had worse endothelial dysfunction irrespective of their coronary heart disease status. 43 The next step was to find if NO dependent pathways are involved, leading to endothelial dysfunction, and it was found that ADMA-which blocks the endothelial NO synthase and prevents NO synthesis-was significantly elevated in patients with major depression. More than that, when depression was relieved at the time of hospital discharge, a significant decrease in arginase activity with an increased L-arginine/ADMA ratio and an increased arginine bioavailability were observed. 9 VEGF has been shown to promote neurogenesis, neuroprotection, and affect synaptic transmission. A meta-analysis (16 articles including 872 patients and 882 controls) found that VEGF levels in the blood of patients with depression were significantly higher than those in controls, and it was suggested that VEGF could be used as a marker of disease activity in 44 Another meta-analysis (14 studies with 1633 patients) supports these results-showing that VEGF levels were significantly increased in subjects with depression compared with healthy controls. 45 Taken together, VEGF could be used as a biomarker for depression and supports the theory that this mediator could be involved in neuroplasticity mechanisms underlying depression. Some reports suggested that during depression there is a state of hyper-permeability of the BBB. 46, 47 Depression is considered a neurodegenerative disease due to inflammation, which may also explain the elevation of VEGF-part of the inflammatory response and activation of blood vessels. 48 VEGF has an effect on neurogenesis, neuroprotection from oxidative stress and benefits on cognitive function. It also increases the permeability of the BBB. 49 It is possible that in order to overcome the oxidative environment in the CNS during episodes of depression, the increased expression of VEGF and the increased permeability of the BBB allows it to enter the brain and participate in neuroprotection and neurogenesis. 44 Because depression is associated with increased cardiovascular morbidity and mortality-that can't be explained by traditional risk factors-and depression has been associated with dysfunction of the immune system and the bone marrow, we hypothesized that depression influences the number and function of bone marrow derived EPCs.
It has been shown that in healthy men levels of EPCs may be a surrogate biologic marker for vascular function and cumulative cardiovascular risk. More than that, flow mediated brachial artery reactivity was an independent predictor of the number of CFU-EPCs, with a striking relation between level of CFU-EPCs and flow mediated brachial reactivity.
11
A study that evaluated the relationship between vascular dysfunction, circulating EPCs and depression found that patients with depression had significantly lower flow mediated diameter (FMD) and a lower percentage of CD34þ/KDRþ EPCs measured by flow cytometry. 50 Among patients with coronary artery disease and depression-a significant decrease in circulating EPCs (CD133þ/CD34þ/KDRþ) was found compared with coronary patients without depression. EPC levels correlated negatively with severity of depression. 50 Unlike previous studies that measured the number of EPCs in the peripheral blood (measured by flow cytometry), our study evaluated the ability (function) to grow colonies in culture, and the number of colonies achieved-as a biomarker of EPCs' viability and capability form colonies and eventually angiogenesis and vasculogenesis.
The finding that EPCs levels are decreased in depressed patients may be secondary to several mechanisms -depletion of the pool of EPCs in the bone marrow, reduced mobility of EPCs, reduced survival and/or differentiation in the peripheral circulation and elevated levels of VEGF. In a recent study we found that circulating VEGF levels were significantly elevated in patients with heart failure compared with healthy controls that correlated with diminished ability to grow in culture CFUEPCs. 51 This finding was consistent with the idea that VEGF plays a compensatory role, reported also in patients with cerebral aneurysm. 51 We have shown that mesenchymal stem cells'
(MSCs) transplantation decreased the high levels of VEGF (that decreased to normal a few months after MSC transplantation) and increased significantly the endothelial function of patients with severe heart failure. 51 Based on these results and on previous studies we suggest that the higher rate of cardiovascular complications observed in patients with depression might be caused by lack of regenerative capacity, impairment of the bone marrow to produce and mobilize EPCs from the bone marrow and to transfer them to the areas of need. These findings could have significant clinical implications for the development of new approaches to treat depression based on the vascular approach, including stem cells (EPCs) enhancement by pharmacological interventions (statins 52 and CXCR4 inhibitors 53 and other means like physical activity. 54 Our previous study 51 established a previously unappreciated therapeutic approach whereby allogeneic MSCs can be employed to stimulate EPCs bioactivity, and decrease unfavourable cytokine mobilization and lower the risk of developing cardiovascular complications and other disorders associated with endothelial dysfunction.
Limitations
The population study was small and the population was limited only to women. Still, the statistical analysis was valid and significant. We recruited only women with major depression, and we are planning to expand our future population of interest also to men with depression, to find a gender-based difference, and the mechanisms behind it. We are planning to increase the population study of patients with depression and to recruit men as well as more women at different ages and with different degrees of depression.
Summary
We have demonstrated that patients with depression had very low counts of EPCs with an impaired function of these EPCs (impaired ability to grow colonies of EPCs) altogether with high levels of VCAM-1 and VEGF, both represent vascular inflammation and activation.
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